-30-01

Ket No.

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 12273-3

Total Pages in this Submission 4

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

| ransmitted her vention entitle | rewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent app | lication for an |
|-----------------------------------|--|-----------------|
| | Plant-Based Vaccines | 1. S. PTO |
| nd invented by | y: | 0 0 0 |
| William H.R. | LANGRIDGE; Jie YU and Takeshi ARAKAWA | 10 |
| a CONTINUA | ATION APPLICATION, check appropriate box and supply the requisite information: | |
| ☐ Continuat | tion Divisional Continuation-in-part (CIP) of prior application No.: | 60/178,403 |
| ☐ Continuat | tion Divisional Continuation-in-part (CIP) of prior application No.: | |
| ☐ Continuat | tion Divisional Continuation-in-part (CIP) of prior application No.: | |
| nclosed are: | Application Elements | |
| 1. ⊠ Filir | ng fee as calculated and transmitted as described below | |
| | | |
| 2. 🗵 Spe | ecification having pages and including the following: | |
| a. 🗵 | Descriptive Title of the Invention | |
| b. 🛚 | Cross References to Related Applications (if applicable) | |
| c. ⊠ | Statement Regarding Federally-sponsored Research/Development (if applicable) | |
| . d. 🗆 | Reference to Microfiche Appendix (if applicable) | |
| e. 🛚 | Background of the Invention | |
| f. 🔀 | Brief Summary of the Invention | |
| g. 🛚 | Brief Description of the Drawings (if drawings filed) | |
| h. 🛚 | Detailed Description | |
| i. 🛚 | Claim(s) as Classified Below | |
| j. 🛚 | Abstract of the Disclosure | |
| | | |

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 12273-3

Total Pages in this Submission

4

| 3. | X | Drawing(s) (when necessary as prescribed by 35 USC 113) |
|------|----|--|
| | a. | |
| ٠ 4. | | Oath or Declaration |
| | a. | ☐ Newly executed (original or copy) ☐ Unexecuted |
| • | b. | ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only) |
| • | C. | ☐ With Power of Attorney ☐ Without Power of Attorney |
| | d. | DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b). |
| 5. | | Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. |
| 6. | | Computer Program in Microfiche |
| 7. | X | Genetic Sequence Submission (if applicable, all must be included) |
| | a. | ☑ Paper Copy |
| : | b. | ☑ Computer Readable Copy |
| | C. | Statement Verifying Identical Paper and Computer Readable Copy |
| | | Accompanying Application Parts |
| 8. | | Assignment Papers (cover sheet & documents) |
| 9. , | | 37 CFR 3.73(b) Statement (when there is an assignee) |
| 10, | | English Translation Document (if applicable) |
| 11. | | Information Disclosure Statement/PTO-1449 Copies of IDS Citations |
| 12. | | Preliminary Amendment |
| 13. | X | Acknowledgment postcard |
| 14. | X | Certificate of Mailing |
| | | ☐ First Class ☒ Express Mail (Specify Label No.): EL442633441US |

Application Elements (Continued)

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 12273-3

Total Pages in this Submission
4

| Accompanying Application Parts (Continued) | | | |
|--|--|--|--|
| 15. | | Certified Copy of Priority Document(s) (if foreign priority is claimed) | |
| 16. | | Small Entity Statement(s) - Specify Number of Statements Submitted: | |
| 17. | | Additional Enclosures (please identify below): | |
| • | | | |
| | | Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2) | |
| 18. | | Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application. | |
| | | Warning | |
| | | An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional. | |
| | | | |
| | | | |
| • | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 12273-3

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed #Extra Rate Fee Total Claims 68 - 20 = \$432.00 48 \$9.00 Х 5 Indep. Claims - 3 = 2 \$40.00 \$80.00 х Multiple Dependent Claims (check if applicable) \$0.00 \$355.00 **BASIC FEE** OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$867.00 A check in the amount of \$867.00 to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 19-2090 as described below. A duplicate copy of this sheet is enclosed. ☐ Charge the amount of as filing fee. ☑ Credit any overpayment. △ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Dated: January 29, 2001 David A. Farah, M.D.

cc: